Grand Pharmaceutical Group Limited 0512

Global bond markets have been hit hard recently, with the UK 30-year gilt yield touching 6%, which is the highest level since 1998. Higher borrowing costs can pressure many sectors, but they often push investors toward businesses seen as essential. In Britain, healthcare is one example. This article highlights three leading UK healthcare stocks from our quality-focused screener that some investors use as a potential anchor in turbulent markets. The stocks covered below are a sample from this...

Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]

Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.

Angelalign Technology Inc. (6699.HK) ("Angel") http://www.angelaligner.com, a global trailblazer in orthodontic clear aligner technology, today announced the launch of Pressure Points in the European market, an upgraded feature that replaces the company's current Torque Ridges. The upgrade reflects Angel's continued commitment to innovation focused on solving orthodontists' clinical challenges.

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies’ cancer drugs. The money buys preferred shares convertible into common stock at an equivalent of $18.36 each, a premium to Summit’s September 28 close of $15.48. […]

Align Technology (NasdaqGS:ALGN) has been highlighted as a key participant in new reports on the global dental equipment market. Researchers cite emerging demand for digital dentistry tools and cosmetic treatments as major drivers in these market assessments. The reports position Align Technology alongside other dental equipment suppliers as exposure to these themes attracts fresh investor attention. Align being profiled as a major player in dental equipment growth is useful context, but not...

Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter earnings.

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, of

The company extended its existing partnership with a major pharmacy chain.

Shares of diversified science and technology company Danaher (NYSE:DHR) fell 3.9% in the afternoon session after the company announced that Julie Sawyer Montgomery assumed the roles of president and chief executive officer and joined the board of directors.

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026 CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or be

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...

Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic Goods Administration (TGA), on 15 September 2026. One year after receiving EU Medical Device Registration, QMID is listed as a Class IIb Medical Device in the Australian Register of Therapeutic Goods (ARTG), making it the first device intended for

TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”). Medicenna is pleased to announce that all of the nominees listed in its management information circul